Injectable & Implantable Delivery Patents: Leaders & Trends 2026
- 52.0% concentration. The five leading assignees account for 3,478 of 6,690 records in scope — over half the field sits with a handful of filers.
- Filings down 69% since the 2021 peak window. From 239 records in 2021 to 73 in 2024, the last year that can be treated as complete before publication lag distorts the count.
- A61K dominates, but devices barely register. 74.9% of records touch medicinal preparations (A61K), while only 4.5% touch body-fluid delivery devices (A61M) — the hardware side is comparatively open.
Filing growth compares 2021 (239 records) with 2024 (73) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 6,690 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks 6,690 patent records filed against injectable and implantable delivery formulations and devices, searched for language tying pharmaceutical injectables and implantable delivery to concrete manufacturing and stability concepts — particle size, release kinetics, fill volume, stability indicators and manufacturing process. That search string matters: it pulls in the formulation science (depot suspensions, biodegradable polymer carriers, thermosensitive release systems) rather than every injectable device patent broadly.
The result skews heavily toward chemistry and biology classes rather than delivery hardware, which shapes how the concentration and white-space findings below should be read.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 6,690-record corpus: how filing volume has moved year over year, and how records distribute across IPC subclasses.
Filing trend: a sharp pull-back from the 2017 peak
Filings peaked in 2017 at 287 records. The clearest comparable window is 2021 to 2024, where volume fell from 239 to 73 records — a 69% drop. Treat 2025 and 2026 figures as still filling in: publication typically lags filing by roughly 18 months, so the most recent years understate real activity rather than confirming a further decline.
Technology composition: chemistry-heavy, device-light
A61K (medicinal preparations) touches 74.9% of records and A61P (therapeutic activity) 41.2%, confirming this corpus is dominated by formulation and pharmacology claims. C07D heterocyclics (32.2%) and C07K peptides/proteins (19.7%) show substantial molecule-class activity, while A61M body-fluid delivery devices sit at just 4.5% — a small footprint relative to the formulation classes above it. Because records can carry multiple IPC classes, these shares sum to more than 100% and should not be added together.
Shares are the percentage of the 6,690 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Injectable & Implantable Delivery Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about injectable & implantable delivery patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaA representative recent filing
Stable paliperidone palmitate composition using thermal treatment (WO2025008726A1)
The filing describes a stable pharmaceutical injectable depot microsuspension of paliperidone palmitate prepared by a wet media milling process that incorporates thermal treatment during manufacturing. The thermal treatment step is presented as producing a depot microsuspension with stable particle size and stable drug release.Filed by Eugia Pharma Specialities Limited, published January 2025 — a manufacturing-process claim on a long-acting injectable depot formulation rather than a new molecule.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5981568A | Therapeutic inhibitor of vascular smooth muscle cells | 982 |
| 2 | US20160208243A1 | Novel crispr enzymes and systems | 863 |
| 3 | US9790490B2 | CRISPR enzymes and systems | 757 |
| 4 | US5702717A | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers | 618 |
| 5 | US6491666B1 | Microfabricated devices for the delivery of molecules into a carrier fluid | 509 |
| 6 | WO2001009111A1 | Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists | 505 |
| 7 | WO2015089351A1 | Compositions and methods of use of crispr-CAS systems in nucleotide repeat disorders | 468 |
| 8 | US5234692A | Delivery device with a protective sleeve | 453 |
| 9 | US5234693A | Delivery device with a protective sleeve | 447 |
| 10 | US20030175410A1 | Method and apparatus for preparing biomimetic scaffold | 420 |
Citation counts reflect an older, heavily-cited core of the corpus and favour records with more time to accumulate citations — read them as influence markers, not as a signal of what matters today.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the ranking, the trend and the IPC mix are read together.
Half the field sits with a handful of filers
The five leading assignees hold 3,478 of the 6,690 records in scope, and the top 10 extend that to 67.6%. New entrants working on core depot-formulation or CRISPR-adjacent delivery chemistry are filing into space already dense with prior art from a small set of pharmaceutical and academic players.
Volume has cooled from its 2017 peak
Filings ran at 287 in 2017 and had fallen to 73 by 2024, the last year the data can be treated as complete. Several of the largest historical filers show near-zero activity in the latest recorded year, though the true current pace is masked by publication lag.
Delivery hardware is thin next to formulation science
A61K medicinal-preparation claims cover three-quarters of the corpus, but A61M body-fluid delivery devices appear in only 4.5% of records. The imbalance suggests device-side claims — pump mechanics, needle-free delivery, fill-volume control hardware — are comparatively under-filed relative to the chemistry around them.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to injectable & implantable delivery patent landscape, with the prior art for and against each one.
Who is filing, and where the ties run
The leader board is short and the drop-off is steep: the top assignee alone holds 1,108 records, more than triple the fifth-place holder's 284.
A single filer dominates volume
The leading assignee's 1,108 records dwarf the rest of the ranked field; fifth place holds 284 and tenth place 172, showing a steep drop after the leader rather than a gradual taper.
Academic-industry pairs file jointly
The strongest co-assignee link in this corpus ties a research institute to a university at 557 shared records, with a pharmaceutical-company pairing following at 279. These pairs point to standing research collaborations rather than one-off joint filings.
Even the biggest historical filers have slowed sharply
Assignees that built large historical portfolios show steep year-on-year drops in the latest recorded year, with some falling to a single filing or none at all. That pattern is consistent with the broader 2021-2024 decline, not specific to any one filer.
| Assignee | Recent year | YoY |
|---|---|---|
| Broad Institute, Inc. | 1 | -92% |
| Massachusetts Institute of Technology | 1 | -92% |
| Eli Lilly and Company | 0 | — |
| Elan Pharmaceuticals, Inc. | 0 | — |
| Wyeth LLC | 0 | — |
| President and Fellows of Harvard College | 0 | -100% |
| The Regents of the University of California | 0 | -100% |
| The Scripps Research Institute | 0 | -100% |
Turning this landscape into a filing decision
The tables above show where the field has been. The next step is testing a specific claim or freedom-to-operate question against it.
Check freedom-to-operate on a formulation claim
Run a specific particle-size, release-kinetics or thermal-treatment claim against the leading assignees' portfolios before drafting.
Explore in Patsnap Eureka →Track momentum on a watch-list assignee
Set up ongoing monitoring on the leaders identified here to catch new filings as publication lag clears through 2025-2026.
Explore in Patsnap Eureka →Map the device-side white space
Compare A61M claim density against the formulation classes to size a device-hardware filing opportunity.
Explore in Patsnap Eureka →Common questions on this landscape
One assignee leads clearly with 1,108 records in this dataset, more than triple the tenth-place holder's 172. The top five assignees combined account for 52.0% of all 6,690 records in scope, and the top ten reach 67.6%. That level of concentration means most new filers are working against prior art already held by a small group of pharmaceutical companies and research institutions rather than a fragmented field.
Filing volume peaked in 2017 at 287 records and had fallen to 73 by 2024, a 69% decline from the 2021 level of 239. However, publication typically lags filing by around 18 months, so the 2025 and 2026 figures in this dataset are still incomplete and should not be read as confirming a continued drop. The safest comparison is the 2021-to-2024 window, which is the most recent period treatable as complete.
Medicinal preparation claims under IPC class A61K appear in 74.9% of the 6,690 records, making formulation chemistry the dominant theme. Therapeutic activity claims (A61P) and heterocyclic compound claims (C07D) follow at 41.2% and 32.2% respectively, while peptide and protein claims (C07K) sit at 19.7%. Delivery device hardware under A61M appears in only 4.5% of records, a much smaller footprint than the chemistry-heavy classes above it.
The clearest gap sits on the device side: A61M body-fluid delivery devices cover only 4.5% of records against A61K's 74.9%, suggesting hardware claims around fill-volume control, needle-free delivery and pump mechanics are comparatively under-filed. Manufacturing-process innovations like thermal treatment during depot microsuspension production, as seen in the representative WO2025008726A1 filing, also appear less contested than the underlying molecule claims they support.
WO2025008726A1, filed by Eugia Pharma Specialities Limited and published in January 2025, claims a stable paliperidone palmitate injectable depot microsuspension made via a wet media milling process that incorporates a thermal treatment step. The claim is centred on the manufacturing process achieving stable particle size and stable drug release, not on the paliperidone palmitate molecule itself. That distinction matters for freedom-to-operate: a different milling or stabilisation route for the same active ingredient may sit outside this particular claim scope.
Research Injectable & Implantable Delivery Patent Landscape in depth with Eureka
Go past this page: query the whole injectable & implantable delivery patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.